Search research articles
Contact Us
Filters
Showing results (1-10 of 69) with videos related to
Page
of 7
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
January 20, 1999
Oral fluoropyrimidines in the treatment of colorectal cancer
N J Meropol
Oncology (Williston Park, N.Y.)
|
July 11, 2000
Oral therapy for colorectal cancer: how to choose
N Damjanov, N J Meropol
Cancer Investigation
|
December 7, 2000
Oral fluoropyrimidines in cancer treatment
N L Lewis, N J Meropol
Seminars in Oncology
|
December 1, 1992
The current status of toxicity protectants in cancer therapy
L M Schuchter, W E Luginbuhl, N J Meropol
Oncology (Williston Park, N.Y.)
|
December 1, 1992
High-dose chemotherapy with autologous stem cell support for breast cancer
N J Meropol, B A Overmoyer, E A Stadtmauer
Perspectives in Biology and Medicine
|
January 1, 1985
Factitious illness: an exploration in ethics
N J Meropol, C V Ford, R M Zaner
American Journal of Clinical Oncology
|
April 16, 1998
Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin
N J Meropol, L E Blumenson, P J Creaven
Current Opinion in Oncology
|
June 29, 2001
Chemoprevention of colorectal cancer
M L Clapper, W C Chang, N J Meropol
Antimicrobial Agents and Chemotherapy
|
March 1, 1981
Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin
H C Neu, N J Meropol, K P Fu
Seminars in Oncology
|
October 1, 1995
Metastatic colorectal cancer: advances in biochemical modulation and new drug development
N J Meropol, P J Creaven, N J Petrelli
Page
of 7
Search research articles
Search
Showing results (1-10 of 69) with videos related to
Sort By:
Page
of 7
European Journal of Cancer (Oxford, England : 1990)
|
January 20, 1999
Oral fluoropyrimidines in the treatment of colorectal cancer
N J Meropol
Oncology (Williston Park, N.Y.)
|
July 11, 2000
Oral therapy for colorectal cancer: how to choose
N Damjanov, N J Meropol
Cancer Investigation
|
December 7, 2000
Oral fluoropyrimidines in cancer treatment
N L Lewis, N J Meropol
Seminars in Oncology
|
December 1, 1992
The current status of toxicity protectants in cancer therapy
L M Schuchter, W E Luginbuhl, N J Meropol
Oncology (Williston Park, N.Y.)
|
December 1, 1992
High-dose chemotherapy with autologous stem cell support for breast cancer
N J Meropol, B A Overmoyer, E A Stadtmauer
Perspectives in Biology and Medicine
|
January 1, 1985
Factitious illness: an exploration in ethics
N J Meropol, C V Ford, R M Zaner
American Journal of Clinical Oncology
|
April 16, 1998
Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin
N J Meropol, L E Blumenson, P J Creaven
Current Opinion in Oncology
|
June 29, 2001
Chemoprevention of colorectal cancer
M L Clapper, W C Chang, N J Meropol
Antimicrobial Agents and Chemotherapy
|
March 1, 1981
Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin
H C Neu, N J Meropol, K P Fu
Seminars in Oncology
|
October 1, 1995
Metastatic colorectal cancer: advances in biochemical modulation and new drug development
N J Meropol, P J Creaven, N J Petrelli
Page
of 7